| 1341 |
National Cancer Institute |
Html |
en |
Smokeless Tobacco and Cancer |
A fact sheet about the health risks associated with the use of smokeless tobacco. |
| tobacco cut size | 0.465919 |
| NCI smoking cessation | 0.353151 |
| safe level | 0.345736 |
| oral tobacco | 0.470575 |
| nicotine addiction | 0.363201 |
| Human Services | 0.340767 |
| Health State-of-the-Science conference | 0.343313 |
| U.S. Department | 0.340786 |
| tobacco-specific nitrosamines | 0.373338 |
| tobacco fertilizer | 0.451995 |
| advisory committee | 0.346137 |
| powdered tobacco | 0.462627 |
| Health Organization International | 0.342988 |
| oral cancer | 0.332186 |
| National Institutes | 0.343448 |
| Watson C. Surveillance | 0.3381 |
| Tobacco Control Monograph | 0.451686 |
| moist snuff | 0.436686 |
| precancerous white patches | 0.344838 |
| International Agency | 0.339252 |
| NCI’s Smoking | 0.334129 |
| Tobacco Research | 0.437462 |
| NCI fact sheet | 0.385333 |
| lower lip | 0.34967 |
| esophageal cancer | 0.332063 |
|
| nicotine stays | 0.353085 |
| Yes. All tobacco | 0.450832 |
| National Cancer Institute | 0.373261 |
| LiveHelp online chat | 0.341688 |
| American snuff | 0.346643 |
| polynuclear aromatic hydrocarbons | 0.347124 |
| Eastern time | 0.340428 |
| spitting tobacco | 0.470917 |
| online text chat | 0.340605 |
| polycyclic aromatic hydrocarbons | 0.346589 |
| smokeless tobacco products | 0.615213 |
| smokeless tobacco cause | 0.576883 |
| Nicotine content | 0.350271 |
| un-ionized nicotine | 0.348074 |
| Surgeon General | 0.344959 |
| smokeless tobacco | 0.995709 |
| Yes. Smokeless tobacco | 0.55885 |
| dry snuff | 0.363969 |
| noncancerous oral conditions | 0.343638 |
| NIH State-of-the-Science Panel | 0.338818 |
| tobacco cause cancer | 0.483342 |
| smoking cessation counselor | 0.38611 |
| tobacco juices | 0.469352 |
| harmful chemicals | 0.350583 |
|
CLICK HERE |
| 1537 |
National Cancer Institute |
Html |
en |
Newcastle Disease Virus (PDQ®)–Health Professional Version |
Expert-reviewed information summary about the use of Newcastle disease virus (NDV) as a treatment for people with cancer. |
| metastatic tumor cells | 0.405592 |
| tumor cell lines | 0.391976 |
| human cancer cells | 0.50054 |
| genetically engineered NDV | 0.389911 |
| NDV oncolysates | 0.413317 |
| autologous tumor vaccine | 0.41773 |
| infected cells | 0.416882 |
| historical control subjects | 0.398257 |
| irradiated ESb cells | 0.39152 |
| Cancer Res | 0.395898 |
| disease virus therapy | 0.398313 |
| virus-modified tumor cells | 0.412589 |
| virus-modified autologous tumor | 0.394368 |
| autologous tumor cell | 0.439505 |
| patients | 0.465722 |
| Natl Cancer Inst | 0.401926 |
| human tumor cells | 0.440276 |
| lytic strains | 0.409693 |
| normal human cells | 0.424643 |
| cell vaccines | 0.393769 |
| et al. | 0.391296 |
| autologous tumor cells | 0.542424 |
| colorectal cancer patients | 0.390231 |
| cancer cells | 0.51627 |
| newcastle disease virus | 0.925041 |
|
| primary tumor cells | 0.39623 |
| PUBMED Abstract | 0.426283 |
| disease virus vaccine | 0.404352 |
| uninfected cancer cells | 0.394475 |
| tumor cells | 0.60365 |
| tumor cell vaccine | 0.404276 |
| progeny virus particles | 0.393227 |
| NDV | 0.533791 |
| Abstract | 0.460011 |
| human immune cells | 0.389104 |
| autologous cells | 0.393227 |
| NDV genetic material | 0.390979 |
| nonlytic NDV strains | 0.407173 |
| NDV-infected cancer cells | 0.395154 |
| malignant melanoma patients | 0.394264 |
| Human tumor cell | 0.388361 |
| renal cell carcinoma | 0.423539 |
| cells | 0.622446 |
| main NDV proteins | 0.390649 |
| ESb cells | 0.400925 |
| NDV strains | 0.410203 |
| regional lymph nodes | 0.425639 |
| cancer | 0.567906 |
| irradiated tumor cells | 0.398885 |
|
CLICK HERE |
| 1649 |
National Cancer Institute |
Html |
en |
Aromatherapy and Essential Oils (PDQ®)–Patient Version |
Expert-reviewed information summary about the use of aromatherapy and essential oils to improve the quality of life of cancer patients. |
| PDQ Aromatherapy | 0.51751 |
| cancer treatment | 0.518478 |
| modern aromatherapy | 0.502296 |
| certain essential oils | 0.545828 |
| aromatherapy training | 0.496531 |
| PDQ cancer information | 0.582174 |
| Cancer Complementary | 0.49782 |
| hormone -like effects | 0.496783 |
| clinical trials | 0.646919 |
| cancer information summary | 0.54045 |
| aromatherapy massage | 0.496545 |
| alternative cancer therapies | 0.488792 |
| clinical trial | 0.515897 |
| CAM cancer research | 0.479249 |
| patients | 0.520207 |
| cancer patients | 0.499565 |
| Aromatherapy products | 0.529674 |
| bergamot essential oil | 0.494855 |
| literature discuss aromatherapy | 0.518185 |
| NCI PDQ cancer | 0.50787 |
| cancer information database | 0.486869 |
| aromatherapy | 0.710126 |
| international aromatherapy programs | 0.515466 |
| Therapies Editorial Board | 0.490712 |
|
| essential oils | 0.964677 |
| cancer information | 0.591001 |
| treatment | 0.540034 |
| Complementary Therapies Editorial | 0.514222 |
| Drug Administration | 0.547203 |
| Cancer Information Specialist | 0.481775 |
| Aromatherapy research | 0.515581 |
| tree essential oils | 0.64448 |
| Cancer Information Service | 0.537651 |
| tree essential oil | 0.496279 |
| Antibacterial essential oils | 0.531896 |
| National Cancer Institute | 0.639762 |
| alternative medicine | 0.561892 |
| standard aromatherapy certification | 0.518782 |
| term aromatherapy | 0.502247 |
| orange essential oil | 0.494346 |
| aromatherapy courses | 0.496618 |
| tea tree | 0.549957 |
| cancer clinical trials | 0.48888 |
| alternative therapies | 0.505894 |
| ginger essential oil | 0.493305 |
| cancer information summaries | 0.487611 |
| cancer | 0.667969 |
| Holistic Aromatherapy | 0.506338 |
|
CLICK HERE |
| 1661 |
National Cancer Institute |
Html |
en |
Antineoplastons (PDQ®)–Health Professional Version |
Expert-reviewed information summary about antineoplastons as a treatment for people with cancer. |
| various tumor suppressor | 0.673325 |
| high-risk pediatric patients | 0.613742 |
| cell lines | 0.732784 |
| antineoplaston A10. | 0.614589 |
| steady state concentration | 0.632482 |
| mean steady state | 0.62987 |
| stable disease | 0.629423 |
| tumor suppressor genes | 0.670419 |
| antineoplaston a10 | 0.785651 |
| multiple brain metastases | 0.666381 |
| clinical trials | 0.642258 |
| cancer cell line | 0.621623 |
| cancer information summary | 0.628466 |
| highest tumor response | 0.628298 |
| patients | 0.960903 |
| cancer patients | 0.782838 |
| average dose | 0.662612 |
| human colon cancer | 0.66679 |
| tumor progression | 0.629611 |
| colon cancer cells | 0.664834 |
| antineoplaston treatment | 0.679278 |
| complete tumor response | 0.726436 |
| metastatic brain tumor | 0.711993 |
| study | 0.663173 |
| neutrophil apoptosis | 0.623745 |
|
| Human/Clinical Studies section | 0.637915 |
| neoplastic cell lines | 0.689948 |
| human blood | 0.654645 |
| cancer cells | 0.75191 |
| animal tumor systems | 0.612469 |
| National Cancer Institute | 0.656232 |
| tumor growth | 0.643714 |
| breast cancer patients | 0.772855 |
| partial tumor response | 0.663127 |
| AS2-1 | 0.676129 |
| antineoplaston therapy | 0.747438 |
| white blood cell | 0.631532 |
| antineoplaston A. | 0.675544 |
| abnormal cells | 0.630356 |
| human tumor tissue. | 0.623365 |
| human urine | 0.617971 |
| antineoplastons | 0.86378 |
| experimental cancer therapy | 0.633011 |
| chronic lymphocytic leukemia | 0.610232 |
| tumor response | 0.767878 |
| objective tumor response | 0.612044 |
| naturally occurring biochemical | 0.637098 |
| antineoplastons A10 | 0.665762 |
| cancer | 0.805413 |
|
CLICK HERE |
| 1688 |
National Cancer Institute |
Html |
en |
Cannabis and Cannabinoids (PDQ®)–Patient Version |
Expert-reviewed information summary about the use of Cannabis and cannabinoids in the treatment of cancer-related side effects, such as nausea and vomiting. |
| cancer treatment | 0.54874 |
| PDQ Cannabis | 0.53541 |
| PDQ cancer information | 0.561631 |
| Cancer Complementary | 0.483651 |
| cancer therapy | 0.493942 |
| clinical trials | 0.738523 |
| cannabinoid receptors | 0.573547 |
| advanced cancer patients | 0.489779 |
| U.S. Food | 0.49892 |
| cancer information summary | 0.529639 |
| National Institutes | 0.485607 |
| alternative cancer therapies | 0.482187 |
| clinical trial | 0.556349 |
| cancer therapies | 0.496308 |
| patients | 0.580973 |
| cancer patients | 0.559766 |
| Cannabis users | 0.54158 |
| Investigational New Drug | 0.490753 |
| NCI PDQ cancer | 0.493719 |
| cancer information database | 0.48226 |
| effects | 0.498728 |
| cannabinoids | 0.769857 |
| main active cannabinoid | 0.509915 |
| treatment | 0.563891 |
|
| breast cancer cells | 0.497802 |
| Cannabis plant extract | 0.540785 |
| United States | 0.581783 |
| Cannabis plant | 0.559258 |
| Complementary Therapies Editorial | 0.487662 |
| Drug Administration | 0.596753 |
| Cancer Information Specialist | 0.479354 |
| cancer cells | 0.516435 |
| Cancer Information Service | 0.529301 |
| Cannabis extract | 0.551963 |
| National Cancer Institute | 0.60295 |
| studies | 0.507275 |
| alternative medicine | 0.50524 |
| pain relief | 0.516491 |
| advanced cancer | 0.497262 |
| approved research settings | 0.478938 |
| cannabis | 0.903862 |
| chemotherapy-related nausea | 0.514076 |
| cancer cell death | 0.500487 |
| medicinal Cannabis | 0.540165 |
| cancer clinical trials | 0.488981 |
| alternative therapies | 0.483937 |
| cancer information summaries | 0.482387 |
| cancer | 0.807964 |
|
CLICK HERE |
| 1798 |
National Cancer Institute |
Html |
es |
Aflicción, duelo y manejo de la pérdida (PDQ®)–Versión para pacientes |
Informe revisado por expertos acerca de la aflicción, el duelo y los sentimientos de pérdida de los sobrevivientes de alguien que murió de cáncer. Se trata también la aflicción en los niños. |
| cope with grief | 0.320516 |
| Helping Children | 0.322023 |
| Dialogue Between Parent | 0.307208 |
| Wolfelt A | 0.31079 |
| Hemisphere Publishing Corporation | 0.30651 |
| siguientes preguntas | 0.304497 |
| Corr CA | 0.321186 |
| aflicción anticipatoria | 0.975865 |
| Do We Tell | 0.306573 |
| baja autoestima | 0.304526 |
| Aflicción normalLa | 0.370032 |
| Aflicción crónica | 0.366865 |
| Instituto Nacional | 0.309451 |
| cansancio extremo | 0.305043 |
| GP Putnam Sons | 0.306438 |
| Mourning Children | 0.305247 |
| familiar cercano | 0.304362 |
| When Someone Dies | 0.30744 |
| siguientes libros | 0.304582 |
| Tiffault BW | 0.304106 |
| años todavÃa | 0.304515 |
| Help Children Participate | 0.307506 |
| TCC ayuda | 0.305556 |
| religión ayuda | 0.304338 |
| muerte ayuda | 0.319844 |
|
| desarrollo edad comprensión | 0.306829 |
| Remember Someone You | 0.30677 |
| muerte expresiones | 0.319738 |
| PDQ Aflicción | 0.353557 |
| conversación).El tratamiento | 0.305805 |
| aflicción anticipatoria ayuda | 0.436499 |
| Publishing Company | 0.310219 |
| National Cancer Institute | 0.305834 |
| anticipatoriaLa aflicción anticipatoria | 0.37147 |
| siguientes riesgos | 0.304531 |
| New York | 0.346791 |
| Children Mourning | 0.305247 |
| siguientes factores | 0.316168 |
| Physician Data Query | 0.319434 |
| MÃnima reacción | 0.30471 |
| Mountain Rainbow Publications | 0.306521 |
| Talking About Death | 0.30672 |
| Springer Publishing Company | 0.306508 |
| Children Cope with | 0.321223 |
| Parent Dies | 0.311854 |
| Tenth Good Thing | 0.306668 |
| Helping Children Cope | 0.321422 |
| Helping Children Understand | 0.308268 |
| Accelerated Development | 0.311496 |
|
CLICK HERE |
| 1894 |
National Cancer Institute |
Html |
es |
Tratamiento del cáncer de pulmón de células no pequeñas (PDQ®)–Versión para pacientes |
Resumen de información revisada por expertos acerca del tratamiento del cáncer de pulmón de células no pequeñas. |
| radiocirugÃa estereotáctica | 0.521736 |
| cuáles ganglios | 0.544229 |
| estadio iv | 0.535294 |
| pequeño corte | 0.516426 |
| sustancia llamada fcev | 0.511226 |
| faja ajustadora | 0.518847 |
| pequeña cantidad | 0.570347 |
| Silbido respiratorio | 0.522024 |
| cáncer.ampliar broncoscopia | 0.521373 |
| gen alk | 0.51503 |
| cáncer.ampliar mediastinoscopÃa | 0.517089 |
| células normales.ampliar exploración | 0.600106 |
| cuerpo.ampliar radiografÃa | 0.522592 |
| estadios ia | 0.514018 |
| rayos x | 0.552576 |
| estadio ib | 0.557189 |
| estadio ia | 0.556394 |
| enlace drugs approved | 0.531609 |
| ondas sonoras | 0.51647 |
| Non-Small Cell Lung | 0.531866 |
| células t | 0.528626 |
| vÃas respiratorias | 0.808836 |
|
| carcinoma epidermoide | 0.525518 |
| numerosos ensayos | 0.516625 |
| pecho.ampliar biopsia | 0.526618 |
| estadios iia | 0.515213 |
| estadio iiia | 0.625519 |
| determinadas células | 0.530359 |
| antecedentes familiares | 0.518918 |
| alta potencia | 0.516655 |
| estadio iia | 0.557019 |
| tirosina cinasa | 0.692486 |
| Cell Lung Cancer | 0.531364 |
| siguientes sitios | 0.51534 |
| siguientes situaciones | 0.666362 |
| ecografÃa ayuda | 0.515534 |
| principal factor | 0.576142 |
| áreas.ampliar biopsia | 0.52208 |
| siguientes formas | 0.529859 |
| bronquiolos.ampliar anatomÃa | 0.52368 |
| siguientes sumarios | 0.532291 |
| siguientes pruebas | 0.527678 |
| vasos sanguÃneos | 0.979174 |
|
CLICK HERE |
| 2021 |
National Cancer Institute |
Html |
es |
Prevención del cáncer de cuello uterino (PDQ®)–Versión para pacientes |
Información revisada por expertos sobre los factores que pueden aumentar el riesgo de cáncer de cuello uterino y los enfoques que podrían ayudar a la prevención de esta enfermedad. |
| Visuals Online | 0.544747 |
| PDQ Exámenes | 0.729141 |
| Internet NCI | 0.599334 |
| siguientes factores | 0.942852 |
| voluntarios sanos | 0.571782 |
| Physician Data Query | 0.821847 |
| Estados Unidos | 0.732136 |
| suficiente ejercicio | 0.608117 |
|
| prevención revisa | 0.577919 |
| PDQ Prevención | 0.648162 |
| cuánto tiempo | 0.58363 |
| National Cancer Institute | 0.579131 |
| invasivo aumenta | 0.607513 |
| siguientes riesgos | 0.566231 |
| siguientes sumarios | 0.745167 |
| Instituto Nacional | 0.648132 |
|
CLICK HERE |
| 2050 |
National Cancer Institute |
Html |
es |
Análisis del antígeno prostático específico (PSA) |
Hoja informativa sobre la prueba del antígeno prostático específico (PSA) y los exámenes selectivos de detección para el cáncer de próstata, y clarifica los beneficios y limitaciones de dicha prueba. |
| posibles complicaciones | 0.529476 |
| United States Preventive | 0.549836 |
| hiperplasia prostática benigna | 0.569875 |
| fusión génica tmprss2-erg | 0.5485 |
| estudio plco | 0.535774 |
| PLCO trials | 0.538088 |
| eréctil o incontinencia | 0.532144 |
| médico quizás | 0.54755 |
| ng per milliliter | 0.54786 |
| concentration-based assay | 0.526257 |
| Pauler DK | 0.526835 |
| structure-based isopsa assay | 0.54715 |
| estudio clÃnico plco | 0.561758 |
| tanta lentitud | 0.531594 |
| posibles perjuicios | 0.59922 |
| riesgos y beneficios | 0.531533 |
| Servicios Preventivos | 0.526931 |
| European Randomised Study | 0.54659 |
| hiperplasia benigna | 0.602949 |
| Preventive Health Services | 0.541802 |
| llamadas isoformas | 0.529743 |
| Screening Draft Recommendations | 0.555159 |
|
| Hugosson J | 0.571924 |
| espectro de isoformas | 0.553214 |
| Instituto Nacional | 0.525806 |
| próstata en asociación | 0.528933 |
| PSA quizás | 0.924082 |
| posibles efectos | 0.527227 |
| Internal Medicine | 0.527548 |
| Services Task Force | 0.63375 |
| among men with | 0.545229 |
| estados benignos | 0.530298 |
| agrandamiento benigno | 0.537792 |
| PubMed Abstract | 0.784346 |
| prostate cancer | 0.975142 |
| estadio inicial quizás | 0.562336 |
| obstante exámenes | 0.563732 |
| New England Journal | 0.630867 |
| Goodman PJ | 0.525307 |
| de 1 muerte | 0.528041 |
| Roobol MJ | 0.576631 |
| pequeños tumores | 0.530536 |
| Heijnsdijk EAM | 0.527351 |
| Hafron JM | 0.526062 |
|
CLICK HERE |
| 3454 |
National Cancer Institute |
Html |
es |
Grados de comprobación científica de los estudios de terapias integrales, alternativas y complementarias en seres humanos con cáncer (PDQ®)–Versión para profesionales de salud |
Información acerca de cómo evaluar la solidez de los datos probatorios obtenidos de los estudios de investigación sobre terapias integrales, alternativas y complementarias en seres humanos con cáncer. |
| Visuals Online | 0.6561 |
| grupo control | 0.658003 |
| Physician Data Query | 0.707803 |
| distintos tipos | 0.676327 |
| mejores casos— | 0.670195 |
| valoración indirectos | 0.860816 |
| tratamiento versus muerte | 0.748944 |
|
| National Cancer Institute | 0.697449 |
| personas ayuda | 0.673043 |
| siguientes riesgos | 0.659857 |
| mejores casos | 0.807578 |
| versus muerte | 0.798627 |
| Instituto Nacional | 0.960893 |
|
CLICK HERE |